Two percent to fifteen percent of patients with gastric cancer (GC) are younger than 45 years of age and there has been an increase in the relative proportion of young age GC compared with older age GC, especially in young females. The question of whether young age GC is different from that of older patients has been raised but remains unresolved. A research article published on January 14, 2010 the World Journal of Gastroenterology addresses this question. The research team from South Korea enrolled, retrospectively, a total of 3242 patients with GC between 18 and 45 years of age and 3000 sex- and age-matched controls. Their study demonstrated that the epidemiologic characteristics including risk factors of young age GC were different according to age and gender.
Pancreatic Cancer Action Network-AACR Pathway To Leadership Grant Awarded To Johns Hopkins Early Career Investigator
The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Zeshaan A. Rasheed, M.D., Ph.D., the 2010 Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant. This grant, totaling $600, 000 over five years, will support Rasheed's efforts to examine the relevance of cancer stem cells in pancreatic adenocarcinoma. Cancer stem cells are a subset of cells hypothesized to mediate the growth and spread of cancer. "This is a critical area of research that will lay the groundwork for new therapies that can effectively treat pancreatic cancer and stem the tide of this devastating, and too frequently fatal, disease, " said Margaret Foti, Ph.
Cancer of the gullet, or oesophagus, is one of the ten most common cancers in the Western world, and there have been recent alarming increases in the number of cases each year in the US and UK. There is no good treatment, and sufferers frequently face a short, painful battle which ends all too quickly in death. Many of the cancers diagnosed are in people with a long history of heartburn. Chronic heartburn leads to the lower parts of the gullet being bathed in a toxic acid solution, and the lining of the gullet defends itself against this by changing itself into something which looks a lot like the lining of the lower intestines. Although the damaged tissue, called Barrett's oesophagus, is not cancerous in itself, its presence warns doctors that the patient has taken the first step towards cancer, and triggers a rigorous programme of monitoring, coupled with therapy to prevent further damage.
Can you catch appendicitis? And if you do, is it necessarily an emergency that demands immediate surgery? Yes and no, according to a new study by UT Southwestern Medical Center surgeons and physicians. The researchers evaluated data over a 36-year period from the National Hospital Discharge Survey and concluded in a paper appearing in the January issue of Archives of Surgery that appendicitis may be caused by undetermined viral infection or infections, said Dr. Edward Livingston, chief of GI/endocrine surgery at UT Southwestern and senior author of the report. The review of hospital discharge data runs counter to traditional thought, suggesting that appendicitis doesn't necessarily lead to a burst appendix if the organ is not removed quickly, Dr.
It is reasonable to obtain a histological diagnosis before treating patients who have pancreatic masses and are unsuitable or unwilling to undergo surgery. As the pancreas is a deep seated organ surrounded by other vital structures, it is a challenge for the physician to obtain an adequate specimen for histological examination. Endoscopic ultrasound-guided biopsy of pancreatic masses has been proved to be a safe and effective method. However, if the hospital has no such facilities or patients are unwilling or intolerant of the procedure, computed tomography (CT)-guided biopsy is an alternative method. A research article published on December 21, 2009 in the World Journal of Gastroenterology addresses this problem.
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide. Surgery alone cannot obtain satisfactory effects in patients with EC. Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs) have been published, but opinions vary among clinicians as to the therapeutic effect of the new method. It remains uncertain whether patients with resectable EC can benefit from neoadjuvant chemoradiotherapy. A research article published on December 21, 2009 in the World Journal of Gastroenterology addresses this problem. The research team from China selected eleven randomized controlled trials (RCTs) including 1308 patients.